<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Therapeutic Drug Monitoring Vankomisin Berbasis Pemodelan Farmakokinetik-Farmakodinamik pada Pasien dengan Infeksi MRSA

dc.contributor.authorHafidz, Ahmad Fadhelal
dc.date.accessioned2026-11-13T08:33:30Z
dc.date.issued2026
dc.description.abstractBackground: Methicillin-resistant Staphylococcus aureus (MRSA) is a major antimicrobial resistance threat associated with high mortality, with vancomycin remaining a primary treatment option. However, its narrow therapeutic index increases the risk of treatment failure and nephrotoxicity. AUC-based therapeutic drug monitoring (TDM) using sparse sampling offers a practical approach, but its implementation in Indonesia remains limited. Objective: To evaluate population pharmacokinetic-pharmacodynamic (PK-PD) modeling of vancomycin based on sparse sampling, identify clinical factors influencing the model, and assess TDM outcomes in patients with MRSA infection. Methods: A prospective cross-sectional study was conducted at Dr. Soeradji Tirtonegoro General Hospital, Klaten, and UGM Academic Hospital. Plasma vancomycin concentrations (1–3 samples per patient) were measured using UHPLC and modeled using a nonlinear mixed-effects (NLME) approach with Monolix and PKanalix 2024R1, with dose simulations performed using Simulx 2024R1. Result: The model developed from 44 subjekts demonstrated good individual predictive performance (outliers <10%), with estimated population parameters of 278.46 L for volume of distribution (Vd), 1.76 L/h for clearance (Cl), 0.20 /h for the elimination rate constant (k), and 3.4 h for the half-life (t½). Covariate analysis showed that BMI and body weight significantly influenced Vd variability, while creatinine clearance influenced Cl. None of the tested covariates significantly affected the pharmacodynamic parameters. TDM evaluation in 10 patients showed that 60% achieved the target Cssmin, 80% achieved the target AUC24/MIC, and 20% achieved the target neutrophil physiological response. Dose-adjustment simulations indicated that the revised regimens could help 4 patients with discordance results return to the therapeutic range. Conclusion: The population PK-PD model adequately characterized vancomycin profiles, with variability influenced by renal function and patient characteristics. Model-based individualized dose simulations suggest that regimen adjustment may help patients who previously failed to achieve therapeutic targets attain more optimal dosing regimens.
dc.identifier.urihttps://repository.uii.ac.id/handle/123456789/67655
dc.publisherUniversitas Islam Indonesia
dc.subjectMRSA
dc.subjectPopulation pharmacokinetic-pharmacodynamic
dc.subjectsparse sampling
dc.subjecttherapeutic drug monitoring
dc.subjectvancomycin
dc.titleTherapeutic Drug Monitoring Vankomisin Berbasis Pemodelan Farmakokinetik-Farmakodinamik pada Pasien dengan Infeksi MRSA
dc.typeThesis

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
22613020.pdf
Size:
6.41 MB
Format:
Adobe Portable Document Format

Collections